Christopher B. Prentiss is CFO at Adamas Pharmaceuticals Inc (ADMS). They have made 9 open-market trades across 1 company since 2018, most recently 2026-07-15.
CIK 0001717583
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADMS | SELL | 2021-03-22 | 2021-03-23 | $5.48 | $13K | -4.8% | -1.8% | -4.4% |
| ADMS | SELL | 2021-02-01 | 2021-02-01 | $6.36 | $24K | -10.1% | -25.2% | -14.4% |
| ADMS | SELL | 2021-01-20 | 2021-01-22 | $4.41 | $12K | +8.4% | +13.4% | +6.8% |
| ADMS | SELL | 2020-11-02 | 2020-11-02 | $3.21 | $7K | +9.0% | +38.3% | +96.8% |
| ADMS | SELL | 2020-01-21 | 2020-01-23 | $5.92 | $8K | -8.3% | -12.6% | -42.8% |
| ADMS | SELL | 2019-07-22 | 2019-07-23 | $6.00 | $6K | +1.7% | +2.2% | -33.3% |
| ADMS | SELL | 2019-03-20 | 2019-03-21 | $8.00 | $9K | -10.7% | -21.0% | -35.1% |
| ADMS | SELL | 2018-12-20 | 2018-12-26 | $7.51 | $2K | +17.2% | +7.6% | -8.3% |
| ADMS | SELL | 2018-03-21 | 2018-03-22 | $25.98 | $15K | +4.1% | +15.3% | +7.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.